Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche v. Biosite

This article was originally published in The Gray Sheet

Executive Summary

San Diego manufacturer Biosite believes patent infringement allegations filed Nov. 9 by Roche in Indianapolis federal court are without merit. The suit references two Roche U.S. patents covering a biosensing meter and a device used for separating plasma or serum from whole blood. Biosite markets the Triage line of drugs-of-abuse assays, cardiac marker test kits and B-type natriuretic peptide (BNP) point-of-care hormone diagnostic tests...

You may also be interested in...

Biosite sues Roche

San Diego firm files complaint in California district court alleging Roche Diagnostics is infringing on two patents related to methods for measuring cardiac troponin forms, according to a Nov. 30 release. The filing marks the second suit Biosite has brought against Roche in recent months. On Nov. 9, the firm brought patent infringement allegations in Indianapolis federal court regarding its biosensing meter and a device used for separating plasma or serum from whole blood (1"The Gray Sheet" Nov. 22, 2004, In Brief)...

Novartis Targets Ten Indications For Cosentyx

The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.

Zydus Cadila Strides Ahead With NASH Filing In India

Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts